Navigation Links
Proton Pump Inhibitor DEXILANT(TM) (dexlansoprazole) Now Available in U.S. Pharmacies
Date:4/26/2010

"When a name change occurs, pharmacists are often the first group of health care professionals that is impacted," noted Marlowe Djuric Kachlic, Pharm.D., clinical assistant professor at University of Illinois at Chicago – College of Pharmacy. "The most important thing for patients, pharmacists and health care professionals to note is that DEXILANT is the same medication as KAPIDEX, with the same safety and efficacy profile."

Individuals and health care professionals who have questions about this name change should contact Takeda at 1-877-TAKEDA-7. Errors involving DEXILANT or any other products should be reported to the FDA MedWatch program online at www.fda.gov/medwatch.

About DEXILANT™ (dexlansoprazole) 30 mg and 60 mg delayed release capsules

DEXILANT is a proton pump inhibitor (PPI), which decreases acid production by turning off many of the acid pumps in the stomach, thus helping to protect the esophagus from acidic reflux so that esophageal inflammation can heal. DEXILANT combines an enantiomer of lansoprazole with a Dual Delayed Release™ (DDR) formulation designed to provide two separate releases of medication. DEXILANT, taken once daily, is approved for the healing of all grades of erosive esophagitis (EE) for up to eight weeks, maintaining healing of EE for up to six months, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Important Safety Information

DEXILANT is contraindicated in patients with known hypersensitivity to any c
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Leading Varian-Equipped Proton Therapy Center Treats 100th Patient
2. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
3. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
4. Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year
5. New Proton Therapy Equipment Enables More Tumors to be Treated
6. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
7. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
8. Neurocrine Advances VMAT2 Inhibitor Program
9. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
10. Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors
11. TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Echo Therapeutics, ... device company focused on skin permeation, continuous glucose ... Scott W. Hollander has been appointed Chief ... has more than 20 years of experience in ... and most recently served as Vice President, Business ...
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... May 25 Two late-breaking clinical trials presented ... clinical data supporting Abbott,s market-leading XIENCE V® Everolimus Eluting ... of more than 5,000 real-world, complex patients, XIENCE V ... at one year (0.84 percent per Academic Research Consortium ...
... 24 At a town hall meeting a year ago, President Obama ... by keeping older people out of more expensive institutional care.  "I actually think ... it helps keep people in their homes," the president told his audience in ... , , ...
Cached Medicine Technology:New Data Reinforces Safety Profile of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent 2New Data Reinforces Safety Profile of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent 3New Data Reinforces Safety Profile of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent 4New Data Reinforces Safety Profile of Abbott's Market-Leading XIENCE V(R) Drug Eluting Stent 5Medicare Policies Ignore Aging-at-Home Concept 2Medicare Policies Ignore Aging-at-Home Concept 3Medicare Policies Ignore Aging-at-Home Concept 4Medicare Policies Ignore Aging-at-Home Concept 5
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... , EAST LANSING, Mich. A team of researchers led ... million to identify risk factors for breast cancer in young ... during a woman,s lifetime. The five-year study, ... Ellen Velie of the College of Human Medicine,s Department of ...
... news release sent yesterday with the removal of the ... background treatments, and forced steroid taper poses an unacceptable ... from a 12-month multi-center clinical trial did not show ... non-life threatening systemic lupus erythematosus (SLE). Abatacept failed ...
... Meeting & OTO EXPO of the American Academy of Otolaryngology ... of ear, nose, and throat doctors in the world, will ... more than 305 scientific research sessions, 594 posters, and several ... a unique opportunity for journalists from around the world to ...
... At the UN Millennium Development Goals (MDG) summit in ... progress on the eight goals agreed in 2000 on ... summit came to a close, governments, businesses and aid ... with particular emphasis on improving maternal and child health. ...
... The loss of a gene known as INPP5A could predict ... of skin cancer, according to a study published today by ... Research Institute (TGen). Targeting INPP5A could provide physicians with ... or SCC, a skin cancer that often spreads to other ...
... scientists from Mayo Clinic, the University of Illinois at ... a long-standing research relationship to apply results from the ... for preterm birth. "This is a collaborative effort ... problems in maternal-fetal health," says Douglas Creedon, M.D., Ph.D., ...
Cached Medicine News:Health News:MSU researcher awarded $14 million to identify breast cancer risk factors 2Health News:Correction: Abatacept found ineffective in treatment of non-life threatening lupus 2Health News:Correction: Abatacept found ineffective in treatment of non-life threatening lupus 3Health News:2010 AAO-HNSF new research daily highlights: Wednesday, Sept. 29, 2010 2Health News:2010 AAO-HNSF new research daily highlights: Wednesday, Sept. 29, 2010 3Health News:2010 AAO-HNSF new research daily highlights: Wednesday, Sept. 29, 2010 4Health News:2010 AAO-HNSF new research daily highlights: Wednesday, Sept. 29, 2010 5Health News:International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health 2Health News:International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health 3Health News:TGen/Mayo Clinic/Arizona Cancer Center study finds gene associated with aggressive skin cancer 2Health News:TGen/Mayo Clinic/Arizona Cancer Center study finds gene associated with aggressive skin cancer 3Health News:Microbiomes may hold key to better understanding of preterm birth 2
CCR Medical conventional laryngoscope handles....
... Wire-Reinforced LMA ™ Airway., ,The ... tube which allows it to be ... while maintaining a good seal. This ... and dental surgery, or other procedures ...
... Airway. , ,Developed for cardiopulmonary resuscitation ... the LMA Fastrach™ has been designed to ... or neck. The LMA Fastrach™ allows continuous ... by emergency teams worldwide including NASA for ...
... in the production of airway ... an integrated solution to all ... single-use Portex Soft Seal Laryngeal ... to this wide portfolio of ...
Medicine Products: